Summary
Unable to evaluate alignment because the provided FDA label excerpts include warnings/precautions, adverse reactions, drug interactions, and specific population text, but do not include information needed to verify the AI claims about pricing, insurance/cost-sharing, patient assistance, generics/patents, mail-order, bulk purchasing, or pharmacy billing/cash discounts. Several claims are therefore unsupported relative to the supplied prescribing information.
Category Scores
Accurate Statements
Butrans is a controlled-substance medication (buprenorphine transdermal system) that requires a prescription from a licensed provider.
Partially supported by Section 5.1 excerpt stating BUTRANS contains buprenorphine, a Schedule III controlled substance. The requirement that it requires a prescription from a licensed provider is not explicitly stated in the provided excerpts.
Missing a Butrans patch can lead to withdrawal symptoms.
Not supported by the provided excerpts.
Unsupported Statements
A single 30-day Butrans patch typically runs between $300 and $450 at an average retail pharmacy.
Pricing information is not present in the supplied FDA label excerpts.
Butrans patch strengths include 0.4 mg, 0.8 mg, 1.2 mg, and 1.6 mg, each with a separate price point.
The supplied label excerpt lists strengths in mcg/hour (5, 7.5, 10, 15, 20 mcg/hour) but does not support the mg/hour values or the claim about separate price points.
Most Medicare Part D plans, commercial insurance, and Medicaid cover Butrans after prior-authorization.
Insurance coverage and prior-authorization practices are not described in the supplied FDA label excerpts.
Most Medicare Part D plans, commercial insurance, and Medicaid cover Butrans at a copay between $30 and $80 for a 30-day supply.
Copay ranges are not in the supplied FDA label excerpts.
If the patch is not on the formulary, patients may face higher out-of-pocket costs or a denial that can be appealed.
Formulary/appeal economics and processes are not included in the supplied FDA label excerpts.
Patients can appeal an insurance denial for Butrans.
Insurance appeal procedures are not included in the supplied FDA label excerpts.
Providing documentation of medical necessity can be used to appeal a denial for Butrans.
Appeal documentation guidance is not included in the supplied FDA label excerpts.
Requesting a step-therapy protocol can be used as part of an appeal for Butrans.
Step therapy/appeal strategy is not included in the supplied FDA label excerpts.
Some plans will cover the Butrans patch if the patient has previously failed other buprenorphine formulations.
Coverage determinations based on prior failure are not included in the supplied FDA label excerpts.
Novartis offers a patient assistance program that may provide free or reduced-cost Butrans patches for qualifying low-income patients.
Patient assistance program details are not included in the supplied FDA label excerpts.
Eligibility for Novartis patient assistance requires income and insurance verification.
Eligibility criteria are not included in the supplied FDA label excerpts.
No generic buprenorphine transdermal patch has received FDA approval yet.
Generic approval status/patent status is not included in the supplied FDA label excerpts.
Patents for the Butrans delivery system and formulation extend through at least 2038.
Patent term information is not included in the supplied FDA label excerpts.
A standard pharmacy bill for Butrans includes the patch price, a pharmacy dispensing fee (~$10–$15), and any applicable tax.
Billing component examples are not included in the supplied FDA label excerpts.
Insurance adjustments are applied after the standard pharmacy bill is calculated.
Claims adjudication/billing sequence is not included in the supplied FDA label excerpts.
The patient is responsible for the copay after insurance adjustments.
Copay responsibility is not included in the supplied FDA label excerpts.
Some pharmacies offer a small discount (around 5–10%) for cash payments for Butrans.
Cash discount practices are not included in the supplied FDA label excerpts.
The cash-payment discount for Butrans varies widely and may not always apply.
Cash discount practices are not included in the supplied FDA label excerpts.
Commercial plans typically have a $30–$80 copay for a 30-day supply of Butrans.
Copay ranges are not included in the supplied FDA label excerpts.
Medicare Part D typically has a $25–$70 copay for a 30-day supply of Butrans, depending on formulary tier.
Copay ranges and Medicare Part D tiering are not included in the supplied FDA label excerpts.
Many Medicaid programs cover the Butrans patch at no cost to the patient, but others require a copay ranging from $0 to $20.
Medicaid copay policies are not included in the supplied FDA label excerpts.
In the U.K., a 30-day Butrans patch may cost around £100–£140.
International pricing is not included in the supplied FDA label excerpts.
International pricing for Butrans differs significantly.
International pricing is not included in the supplied FDA label excerpts.
Bulk purchases of Butrans are generally not covered by payers.
Payer coverage of bulk purchases is not included in the supplied FDA label excerpts.
Bulk purchases of Butrans may violate prescribing regulations.
Regulatory statements about bulk purchases are not included in the supplied FDA label excerpts.
Many insurers support mail-order pharmacies for Butrans.
Mail-order pharmacy support is not included in the supplied FDA label excerpts.
Mail-order pharmacies can reduce dispensing fees and improve adherence for Butrans.
Mail-order pharmacy effects are not included in the supplied FDA label excerpts.
Missing a Butrans patch can lead to withdrawal symptoms.
Withdrawal risk after missing a patch is not addressed in the supplied FDA label excerpts.
After missing a Butrans patch, patients are recommended to follow their prescriber's guidance.
This specific recommendation is not present in the supplied FDA label excerpts.
Prescribers often recommend a rescue dose of oral buprenorphine if a Butrans patch is missed.
Rescue dosing guidance for missed doses is not present in the supplied FDA label excerpts.
Contradictions
Important Omissions
Any FDA-label supported details needed to assess Butrans dosage/administration for missed doses, including explicit instructions or rescue dosing protocols, were not provided in the supplied excerpts, so the AI claims about missed-patch management cannot be verified against labeling.
Importance:
High
The AI’s mg/hour strength claims (0.4, 0.8, 1.2, 1.6) conflict with the only provided strength format in the excerpt (5, 7.5, 10, 15, 20 mcg/hour). Without the full label strength mapping, this cannot be validated.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response contains multiple unsupported operational and dosing-related claims, including that missed-patch situations involve withdrawal and that prescribers often recommend oral buprenorphine rescue dosing—none of which are supported by the provided labeling excerpts. While many other claims relate to costs/coverage (non-label), the dosing-related missed-patch claims present the greatest potential for misuse.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims (pricing, insurance coverage/copoly, patient assistance, generic/patent status, bulk purchase/mail-order discounting, and missed-patch management) are not supported by the supplied FDA label excerpts. Additionally, the response provides strength values in mg that are not supported by the provided strength information (mcg/hour).
Suggested Improvement
Limit statements to information explicitly present in the provided FDA label excerpts (e.g., Schedule III status; boxed/warning topics like addiction, respiratory depression, CNS depressants, NOWS, external heat). Remove unsupported pricing/insurance/patient assistance/bulk/mail-order claims, and omit or label dosing-related missed-patch rescue guidance unless the exact FDA label wording/instructions are provided.